Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 27, 2024 2:49pm
144 Views
Post# 35902076

RE:RE:RE:RE:RE:RE:RE:RE:RE:Very strange , even for ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:Very strange , even for ONC

The important stuff?
Oncolitics biotech is in deep with a Roche. 

The Gobblet trivial started a few years ago. Now seeing progress 
recently & in Onc or any biotech world, getting FDA fast track recognition to adnave to phase 3 with the Pancreatic cancer arm. And moving forward with most recent tye anal cancer arm.
The third arm I can't recall. Perhaps those who spend countless hours correcting me, can validate the 3 rd opportunity they are progressing along with Roche ( tecentriq co- therapy).?
Regarding the Microsoft to Onc comparison? Not at all insinuating they are remotely the same.
The investment advice however is the same. Bill gates divested billions from Microsoft. Not because he had misgivings towards the company. Simple ( perhaps complicated for the likes of those who can't get beyond finding faults with meaningless statements) .. logic. 
simple logic.
Too many eggs in one basket, regardless of the basket size or contents.
i have never disclosed before. A few on here know me personally & have talked email & phone.
I was raised very poor. Single mom, back before it was common.
Today? My professionaly managed portfolio in excess of $1.3 million.Onc is not  part of that.
I do dabble in a few stocks.
onc being one of a handful...I have been using my dividends from my blue chip stocks to buy more Onc.
averaging down. 
Should Onc fail, I'll be disappointed, but I won't be broke, or even miss a meal.
Should they get Pela to market and/ or a buyout. I'll be quite happy.
Probably buy a Tesla, or two. Cars not stocks lol
bottom line for me?
I believe in Onc, it's product Pelareorep.
Roche would not put their good name into a 4 arm trial. Now advancing to next phases in 3 of the arms, without strong clinical evidence.
onc mangement? Easy to throw stones. 

onc mangement arranged a great deal with PanCan,.
That deal was cancelled not by Onc or because of ONC....PanCan essentially closed down. The precision promise program.
Putting Onc into a very difficult situation at a very bad time.
none of the science has changed.
The FDA fast track for MBc & panc cancers still exists.
What is not in place is the $$$ to move forward.
THAT is all that matters going forward, Not who said what or when in this board or any. Not if people have projected buyouts in many billions or complete failures.
The answer MUST come to light , very soon.
predict, bash, promote, put down, all you want.
none of it matters.
new investors? 
Those who bought in on the last dip a week or so ago, are up a reasonable %.
question then becomes, where is the upside?
Im in for the long haul. Good news & I come into @ lot of extra spending $$.
bad news?
Money I have already spent.
great day all.
again a challenge for those who work so hard at correcting me.
please update on the 3rd arm of the Gobblet trial, that was successful.
Two being Pancreatic & Anal.

i just can't remember.
 

regards


 



 

<< Previous
Bullboard Posts
Next >>